28results about How to "Inhibit progress" patented technology

The invention discloses a medicine for treating osteoarthritis, and belongs to the field of medicine, the medicine comprises a reagent capable of stimulating chondrocyte development, and the medicine L-arginine can promote expression of chondrocyte anabolic factors and reduce expression of cartilage degradation markers, so that chondrocytes are protected to a certain extent; in addition, the medicine provided by the invention has an excellent cartilage repair function, can inhibit the progress of degenerative osteoarthritis, has good biocompatibility, and has no cytotoxicity to cartilage cells.

The invention discloses an antigen peptide polymer vesicle tumor vaccine as well as a preparation method and application thereof. The antigen peptide polymer vesicle tumor vaccine is obtained by assembling and cross-linking a polymer pre-grafted with antigen peptide and a block polymer and loading an immunologic adjuvant through electrostatic interaction. The vesicle system disclosed by the invention has the advantages of small size, simplicity and controllability in preparation, excellent biocompatibility, high in-vivo circulation stability, targeting of main immune organs, intracellular delivery of antigen peptides and the like. The vesicle nano vaccine displaying the antigen peptide on the surface and encapsulating the immunologic adjuvant can promote dendritic cell maturation and antigen presentation, improve the specific response of mice to tumor-associated antigens, effectively inhibit tumor growth, remarkably prolong the lifetime of tumor-bearing mice and induce a strong immune protection effect, and is high in safety and easy to popularize. A multifunctional'ready-to-use 'nano vaccine concept is embodied, a flexible platform is provided, and different peptide antigens and / or adjuvants can be used for treating different cancers.

The invention discloses a traditional Chinese medicine effective component compound preparation for inhibiting colorectal cancer transformation, which is composed of palmatine, berberine, coptisine and aesculin, and the mass ratio of the palmatine to the berberine to the coptisine to the aesculin is 3: 3: 1: 3. The traditional Chinese medicine active ingredient compound preparation can be prepared into clinical common preparations including granules, capsules or oral liquid according to a conventional method. The traditional Chinese medicine effective component compound preparation disclosed by the invention is proved to be capable of inhibiting intestinal inflammation, improving the intestinal barrier function and remarkably inhibiting colorectal tumor in an inflammatory state by intervening a mouse DSS induced chronic colitis model and an AOM / DSS combined induced colitis and proctitis cancer transformation model.

The invention provides a USP9X protein allosteric activator T7150 and application of the USP9X protein allosteric activator T7150. It is found for the first time that T7150 induces allosteric deubiquitination enzyme USP9X, enhances the activity of the deubiquitination enzyme USP9X, meanwhile, it is found that T7150 inhibits absorption of macrophages to ox-LDL and reduces formation of foam cells, it is indicated that T7150 can prevent formation of foam cells, and therefore T7150 can be used for inhibiting the progress of atherosclerotic plates. On the other hand, the invention also finds that the T7150 obviously reduces lipid deposition in atherosclerotic plaques and obviously reduces the lipid content in the plaques, which also shows that the T7150 can effectively inhibit the progress of atherosclerosis.

The invention discloses a biaryl compound with necroptosis resisting activity as well as a derivative and application of the biaryl compound. The biaryl compound is a compound as shown in # imgabs0 # or a pharmaceutically acceptable salt of the biaryl compound. The synthesis method of the compound is simple, and the obtained compound can inhibit in-vitro necrotic apoptosis of HT-29 cells and can relieve hepatic fibrosis progress of a schistosome infected mouse model. The compound can be used for preparing drugs for treating and / or preventing inflammatory, fibrosis, infectious, ischemic, degenerative or tumor diseases caused by necrotic apoptosis, and has a good market prospect.

The invention relates to the field of biological medicines, and discloses a preparation method and application of a neutralizing antibody capable of effectively inhibiting dryness of gallbladder cancer cells and progress of gallbladder cancer and remarkably improving the lifetime and prognosis of a patient. A gene sequence for coding the humanized anti-FZD6 monoclonal neutralizing antibody comprises a sequence of a heavy chain variable region and a sequence of a light chain variable region. The gene sequence of the heavy chain variable region is as shown in SEQ ID NO: 1, and the gene sequence of the light chain variable region is as shown in SEQ ID NO: 2. The neutralizing antibody targets a non-classical Wnt pathway receptor FZD6, so that the activation of a Wnt / Ca < 2 + > signal pathway can be effectively inhibited, and the migration and growth of gallbladder tumor cells can be inhibited. Experimental detection proves that the FZD6 neutralizing antibody can effectively block the interaction between Wnt5a-FZD6-mediated tumor-related fibroblasts and gallbladder cancer cells, remodel the gallbladder cancer immunosuppressive tumor microenvironment and inhibit the dryness of gallbladder tumor cells and the migration and growth of gallbladder cancer cells, and can be applied to preparation of gallbladder cancer specific targeting drugs.

The invention belongs to the technical field of traditional Chinese medicine, and particularly discloses a traditional Chinese medicine composition for treating fibromyalgia syndrome and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from radix polygoni multiflori preparata, fructus citri sarcodactylis, radix pseudostellariae, caulis spatholobi, flos rosae rugosae, rhizoma dioscoreae, semen lablab album, rhizoma curcumae longae, lucid ganoderma, arillus longan, flos albiziae and fructus ziziphi jujubae. The traditional Chinese medicine has the effects of soothing liver and strengthening spleen, nourishing and activating blood, calming heart and tranquilizing mind, and activating meridians Pharmacodynamic experiment research and clinical observation results show that the traditional Chinese medicine composition can significantly relieve pain of patients and improve depressive symptoms, and can be used for treating fibromyalgia syndrome.

This invention discloses the application of a PDLIM2 gene overexpression viral vector in the preparation of drugs for treating podocyte disease, wherein the nucleotide sequence of the PDLIM2 gene is shown in SEQ ID NO:1. This invention is the first to discover and verify the core role of the PDLIM2 gene in podocyte protection, confirming its significant downregulation in DKD and FSGS disease models, and demonstrating through functional experiments that PDLIM2 overexpression can effectively stabilize the podocyte cytoskeleton, inhibit apoptosis, and reduce proteinuria, thus establishing it as a key target gene for the treatment of podocyte disease. This invention is the first to intervene at the gene level in the core link of podocyte damage—cytoskeleton stability. By specifically upregulating the expression of PDLIM2 in podocytes, it directly enhances their intrinsic cytoskeleton support and anti-damage ability, achieving a fundamental shift in treatment strategy from "symptomatic support" to "causal repair."

Provided are a composition for treatment and the like of bovine papillomatosis caused by bovine papillomavirus, and a method using the same. Provided are a composition for treatment, amelioration, and / or suppressing the progression of bovine papillomatosis caused by bovine papillomavirus, the composition containing, as an active ingredient, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound; and a method for treating, ameliorating, and / or suppressing progression of, bovine papillomatosis caused by bovine papillomavirus, the method including administering, to a cow, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound:

The invention discloses an application of paclitaxel in preparation of an anti-breast cancer drug. The invention proposes and verifies that taxafen effectively down-regulates WDYHV1 protein expression of tamoxifen drug-resistant breast cancer cells and induces ferroptosis of cancer cells for the first time, so that the activity of tamoxifen drug-resistant tumor cells is remarkably reduced, the development of breast cancer is inhibited, and a new direction is provided for treatment of tamoxifen drug-resistant lung cancer.

The present invention discloses a BP-PEI@RNA nano-drug complex, a preparation method and its application in treating cancer. The BP-PEI@RNA nano-drug complex is composed of RNA and BP modified by PEI. The nano-drug complex can achieve efficient and stable delivery of RNA, transport exogenous gene drugs (RNA) into tumor cells, and inhibit the progression of prostate cancer by increasing the expression level of tumor suppressor genes in tumor cells, and has good clinical application prospects.

The utility model relates to an adjustable toe pad, and relates to the technical field of nursing materials. The utility model discloses a toe correcting device which comprises a bottom pad and a plurality of correcting sleeves, the correcting sleeves are all located on the same side of the bottom pad, a plurality of correcting holes are formed in the bottom pad in a penetrating mode, the correcting holes and the correcting sleeves are arranged at intervals in an arc shape in the direction of toes, the two ends of any correcting sleeve penetrate through the corresponding correcting holes respectively, and the correcting sleeves are detachably connected with the bottom pad. Firstly, a foot is placed on the bottom pad, then toes are put into the corresponding correction sleeves, the correction sleeves are detachably connected with the bottom pad, wearing and dismounting are facilitated, and the installation number of the correction sleeves and the installation distance between the two ends of the correction sleeves can be adjusted according to the actual situation of a user; the correcting sleeve separates the toes from one another, so that toe seams are kept in a breathable state, sweat stains can be effectively absorbed, sweating, secretion generation and adhesion of the toe seams are reduced, and occurrence and development of diabetic feet can be effectively prevented and delayed.

This invention belongs to the field of novel carbon nanomaterials technology, and discloses a Clostridium butyricum-derived carbon dot boat-shaped nanoparticle, its preparation method, and its application. The preparation method includes the following steps: Step 1, Clostridium butyricum is cultured to the logarithmic growth phase, and then placed in a pretreatment solution for suspension incubation to regulate the structural integrity and surface chemical composition of Clostridium butyricum cells. The pretreatment solution is an aqueous solution of EDTA, NaCl, or PEG-8000. After incubation, the precipitate is collected by centrifugation, washed, and resuspended in ultrapure water; Step 2, the Clostridium butyricum treated in Step 1 is placed in a high-pressure reactor for hydrothermal reaction to obtain a crude product system; Step 3, the crude product system is filtered and purified, and freeze-dried to obtain Clostridium butyricum-derived carbon dot boat-shaped nanoparticles. The nanoparticles prepared by this invention have uniform particle size, good water solubility, dispersibility, and biocompatibility, and exhibit significant immunomodulatory functions.

The invention relates to the technical field of biological medicines, and discloses an application of a composition of Tazofelone and taxus medicines in treatment of solid tumors. According to the application disclosed by the invention, the condition that the combination of the Tazofelone and the paclitaxel medicines can be used for treating the generic solid tumors is proposed for the first time, and the tumor killing effect of the low-concentration paclitaxel medicines can be obviously improved by the Tazofelone. The PTCs model is used for simulating the tumor microenvironment, and the drug screening result and the clinical result have high correlation. According to the invention, a plurality of solid tumor PTC models are constructed, and the effects of singly using Tazofelone and jointly using Tazofelone and paclitaxel on inhibiting the progress of the generic solid tumor are detected by detecting the area of PTCs, the ATP content and other indexes. Results show that the development of various solid tumors can be effectively inhibited when the Tazofelone is combined with the paclitaxel, the Tazofelone can obviously enhance the effect of the paclitaxel, the dosage of the paclitaxel can be properly reduced during clinical use, and adverse reactions are reduced while the development of the tumors is effectively inhibited, so that the Tazofelone and the paclitaxel have great application potential clinically.

The invention discloses a micromolecular drug targeting ELF1 and application of the micromolecular drug in intervertebral disc degeneration, and belongs to the technical field of biological medicine, it is found for the first time that the micromolecular compound Mycopherolate Mofetin has a treatment effect on intervertebral disc degeneration, in-vivo and in-vitro verification experiments show that the micromolecular compound Mycopherolate Mofetin has a remarkable inhibition effect on senescence of nucleus pulposus cells, and the micromolecular drug can be used for treating intervertebral disc degeneration. According to the present invention, the application of the Mycopherate Mofetil in the treatment of intervertebral disc degeneration is provided, the progress of intervertebral disc degeneration is significantly inhibited, the new method and the new idea are provided for the clinical treatment of intervertebral disc degeneration, and the significant significance in the adjuvant treatment and prevention of intervertebral disc degeneration is provided, such that the small molecule compound Mycopherate Mofetil has the good clinical application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an mTOR inhibitor to improvement of sleep disorders. Aiming at the defects of the existing hypnotics, the invention finds that the sleep disorder can be improved by using the Rapamycin through researching a new sleep pathway target. The Rapamycin disclosed by the invention is a non-addictive sleeping drug, and can induce natural sleep behaviors; compared with an existing clinical hypnotics which has the side effect of greatly increasing the death rate, the Rapamycin administration disclosed by the invention is beneficial to improving the sleep quality and prolonging the life of animals at the same time. The invention discloses a remarkable effect of Rapamycin in the aspect of improving the sleep disorder, and the discovery has important significance in improving the sleep quality of a patient and preventing the progress of diseases, so that the Rapamycin has a wide medical prospect and a remarkable economic value.

The invention discloses a biological bionic hybrid membrane coated Prussian blue nano-enzyme, which comprises a Prussian blue nano-enzyme and a neutral granulocyte membrane (N)-macrophage membrane (M) hybrid membrane (NM hybrid membrane), and the Prussian blue (PB) nano-enzyme is coated in the NM hybrid membrane. Compared with an N-PB nano-enzyme and an M-PB nano-enzyme, the hybrid membrane NM-PB nano-enzyme is remarkably improved in the aspects of targeting force and ulcerative colitis treatment.

Provided is a pharmaceutical composition for treatment of mucopolysaccharidosis type I patients. Here, the patient has a disorder particularly in the central nervous system. A pharmaceutical composition containing, as an active ingredient, a fusion protein of an anti-human transferrin receptor antibody and human α-L-iduronidase is administered to a patient with mucopolysaccharidosis type I by intravenous infusion at a dose of 0.1 to 10 mg / kg body weight. The administration is performed continually for at least 3 months at intervals of 5 days to 21 days. This decomposes dermatan sulfate and heparan sulfate accumulated in the tissues of the patient, particularly in the central nervous system.

The invention discloses application of a core sequence FAM99Bcore and GalNAc-FAM99Bcore, which are used for combining FAM99B with DDX21 and promoting cutting and degradation of the DDX21, in treatment of liver cancer. The GalNAc-FAM99Bcore can be used for effectively inhibiting the in-vivo progress and metastasis of the nude mouse liver orthotopic xenograft tumor, and has a very high clinical transformation value and a very high market prospect.

The invention relates to the technical field of medicines, in particular to application of PTX3 protein in auxiliary diagnosis and treatment of ovarian cancer peritoneal metastasis. Immunohistochemical experiments show that the expression of PTX3 in peritoneal metastasis tissue is obviously higher than that of primary tumor tissue, and the high expression of PTX3 is in positive correlation with clinical staging and metastasis conditions of patients. Through overexpression and knock-down experiments of PTX3, the overexpression of PTX3 significantly promotes the proliferation, migration and invasion ability of ovarian cancer cells, and the knock-down of PTX3 significantly inhibits the proliferation, migration and invasion ability of ovarian cancer cells. In-vitro experiments comprehensively verify the key effect of PTX3 in ovarian cancer peritoneal metastasis, the importance of PTX3 as a diagnosis and treatment target is defined, and a scientific basis is provided for formulation of clinical diagnosis and treatment schemes.

A pharmaceutical combination comprising (a) a B-Raf inhibitor, (b) a EGFR inhibitor and, optionally, (c) a PI3K inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

The invention discloses application of a PDLIM2 gene overexpression virus vector in preparation of a medicine for treating podocytosis. The nucleotide sequence of a PDLIM2 gene is as shown in SEQ ID NO: 1. The core effect of the PDLIM2 gene in podocytosis protection is found and verified for the first time, it is confirmed that the expression of the PDLIM2 gene in DKD and FSGS disease models is remarkably reduced, and functional experiments prove that the overexpression of the PDLIM2 can effectively stabilize podocytoskeleton, inhibit apoptosis and relieve proteinuria, so that the PDLIM2 gene is determined as a key target gene for treating podocytosis. According to the invention, the stability of the cytoskeleton, which is a core link of podocyte injury, is intervened from the gene level for the first time. The expression of the PDLIM2 in the podocyte is specifically up-regulated, so that the internal cytoskeleton support and damage resistance of the podocyte are directly enhanced, and the fundamental treatment strategy conversion from symptomatic support to cause repair is realized.

This invention discloses the application of the compound pimozide in combination with metronidazole in the preparation of a drug for improving oocyte quality and treating endometriosis-related fertility disorders, belonging to the field of biomedical technology. The efficacy of this invention was verified by constructing mouse models of endometriosis driven by pathogenic *Prevotella bisporus* and mouse models of ovarian endometriosis. Experimental results showed that the combined administration significantly eliminated *Prevotella bisporus* colonizing ectopic lesions, reduced succinic acid content in both eutopic and ectopic lesions, decreased the succinylation level of lysine residue 195 of the ACADVL protein, reduced the fluidity of primary endometrial epithelial cell membranes, reduced the volume and weight of endometriotic lesions, and improved oocyte spermatogenesis, ovulation rate, and litter size. This invention solves the problem that existing therapies cannot simultaneously control endometriosis lesions and protect reproductive function, providing a new, safe, and effective combined treatment option for patients with endometriosis and infertility.

The invention belongs to the technical field of biological medicines, and particularly discloses application of an OSBPL3 inhibitor in preparation of a medicine for treating and / or preventing colorectal cancer. By constructing an OSBPL3 knock-down mouse CRC model, it is clear that down-regulation of OSBPL3 can inhibit the progress of CRC of mice, through comparative analysis of a disease group and an intervention group, a tumor immune biological process containing intestinal microbiota-metabolite-differential genes is found, and it is clarified that down-regulation of OSBPL3 in vitro can promote proliferation of peste des petits ruminants and rhomonas rugosa. A CRC model of a flora transplantation mouse is constructed, and it is verified that when key microorganisms (peste des petits ruminants and rhodomonas) are applied to intestinal flora transplantation, the tumor immune surveillance function can be enhanced, and occurrence and development of CRC are inhibited.

The present application relates to the technical field of biological medicine, disclose a kind of new use of human-derived miR-335-3p and the method for regulating target gene IL-16 expression, its new use is to inhibit yellow ligament cell fibrosis, and hsa-miR-335-3p can be targeted to bind IL-16 mRNA 3'UTR, the 8mer binding site of human-derived miR-335-3p and IL-16 mRNA 3'UTR exists, located at 775-782 of 3'UTR, to inhibit the expression of IL-16 gene, and interfere with the function of IL-16 gene to promote yellow ligament hypertrophy, it has wide application prospect on the drug related to lumbar yellow ligament hypertrophy, based on the present application can be made to treat or prevent the disease related to lumbar yellow ligament hypertrophy drug or detection kit.

The invention belongs to the technical field of medical and dental preparations, and provides siRNA of a targeted PITX2 gene and a medicine and application of the siRNA, the medicine is used for preventing and treating periodontitis and comprises the siRNA of the targeted PITX2 gene, and the siRNA is specifically combined with and targets mRNA of the PITX2 gene, so that expression of the PITX2 gene is blocked, and generation of inflammatory epithelial cells SAA1 + Epi in periodontal tissue is inhibited. According to the invention, the absorption degree of alveolar bone can be obviously reduced, and the progress process of periodontitis can be delayed.

The invention relates to the technical field of biology, and provides application of TLQP-21 in treatment of pancreatic cancer or pancreatic cancer-depression co-disease. The application reveals that the TLQP-21 has the effect of inhibiting pancreatic cancer progression, can improve depression-like behaviors and pain symptoms, provides a novel target for the development of pancreatic cancer and pancreatic cancer-depression co-disease medicines, also provides a new treatment strategy for the pancreatic cancer and pancreatic cancer-depression co-disease medicines, is expected to be clinically used, provides an effective treatment method, and has a wide application prospect. The life quality of pancreatic cancer patients is improved, the survival time is prolonged, and a new research direction is provided for treatment of pancreatic cancer and pancreatic cancer-depression codiseases.

The application provides an effect and application of CREPT in fatty liver disease and complications thereof, in particular, application of CREPT gene or protein as a target or a reagent for targeting the CREPT gene or protein in treatment of metabolic-related fatty liver disease and fatty liver disease complications or in preparation of a medicine for treating metabolic-related fatty liver disease and fatty liver disease complications, and the metabolic-related fatty liver disease and fatty liver disease complications are treated by reducing the expression of the CREPT gene or reducing the function or inactivating the CREPT protein. The present application firstly finds that the CREPT is closely related to the metabolic-related fatty liver disease: the systemic or local medication can effectively treat the metabolic-related fatty liver disease and fatty liver disease complications by reducing the expression of the CREPT.